Wako, 138-09991, Medroxyprogesterone Acetate

Primary follicles mature into Graafian follicles by the action of FSH, and begin to secrete estradiol. This estradiol causes the endometrium to proliferate, while FSH secretion is inhibited (feedback control), resulting in enhanced LH secretion. Graafian follicles are stimulated by LH, and proceed to ovulation and luteinization. LH stimulates the corpus luteum to secrete progesterone, enhances the development of uterine gland tubes and shifts the endometrium to the secretory phase (fully functioning state), while progesterone decreases oxytocin susceptibility of the uterus.Physiological effectFollicular hormone (estradiol); 1. Proliferation of endometrium2. Expression of secondary sexual characteristics3. Increased oxytocin sensitivity of the uterus4. Inhibition of FSH secretion (feedback control)Corpus luteum hormone (progesterone); 1. Changes the endometrium into a secretory phase endometrium (implantation of fertilized egg)2. Hyperthermic action (stimulation of heat center)3. Inhibition of LH secretion4. Reduction of oxytocin susceptibility of the uterus (prevention of miscarriage)Luteinizing hormone agonist having an antitumor activity. Neovascularization inhibitor. Corpus luteum hormone agonist with antitumor activity., Luteinizing hormone agonist with antitumor activity. It has attracted attention as a neovascularization inhibitor.